- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02446444
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer (ENZARAD)
Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Blacktown Hospital
-
Campbelltown, New South Wales, Australia, 2560
- Campbelltown Hospital
-
Camperdown, New South Wales, Australia, 2050
- Chris O'Brien Lifehouse
-
Gateshead, New South Wales, Australia, 2290
- Genesis Cancer Care Newcastle
-
Gosford, New South Wales, Australia, 2250
- Gosford Hospital
-
Kogarah, New South Wales, Australia, 2217
- St George Hospital
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
Orange, New South Wales, Australia, 2800
- Orange Health Service
-
Randwick, New South Wales, Australia, 2131
- Prince of Wales Hospital
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Australia, 2010
- St Vincent's Hospital
-
Tamworth, New South Wales, Australia, 2340
- Tamworth Rural Referral Hospital
-
Wahroonga, New South Wales, Australia, 2076
- Sydney Adventist Hospital
-
Waratah, New South Wales, Australia, 2298
- Calvary Mater Newcastle
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
Wollongong, New South Wales, Australia, 2500
- Wollongong Hospital
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- Genesis Cancer Care Queensland - Wesley and Chermside
-
Douglas, Queensland, Australia, 4814
- Townsville Hospital
-
Herston, Queensland, Australia, 4006
- Royal Brisbane & Womens Hospital
-
Nambour, Queensland, Australia, 4560
- Nambour General Hospital
-
South Brisbane, Queensland, Australia, 4101
- Radiation Oncology Services Mater Centre
-
Southport, Queensland, Australia, 4215
- ICON - Gold Coast (formerly ROC Gold Coast)
-
Toowoomba, Queensland, Australia, 4350
- ICON - Toowoomba (formerly ROC Toowoomba)
-
Tugun, Queensland, Australia, 4224
- Genesis Cancer Care Queensland - Tugun and Southport
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital Brisbane
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
Bedford Park, South Australia, Australia, 5042
- Flinders Medical Centre
-
Kurralta Park, South Australia, Australia, 5037
- Ashford Cancer Centre Research (Adelaide Cancer Centre)
-
-
Tasmania
-
Hobart, Tasmania, Australia, 7000
- Royal Hobart Hospital
-
-
Victoria
-
Bendigo, Victoria, Australia, 3550
- Peter MacCallum Cancer Centre
-
Bentleigh East, Victoria, Australia, 3165
- Peter MacCallum Cancer Centre (Moorabbin Campus)
-
Box Hill, Victoria, Australia, 3128
- Eastern Health (Box Hill Hospital)
-
Epping, Victoria, Australia, 3076
- Genesis Care - Epping (formerly EROC)
-
Footscray, Victoria, Australia, 3011
- Genesis Care - Western (formerly WROC)
-
Frankston, Victoria, Australia, 3199
- Genesis Care - Frankston (formerly FROC)
-
Heidelberg, Victoria, Australia, 3084
- Austin Health
-
Melbourne, Victoria, Australia, 3002
- Peter MacCallum Cancer Centre
-
Richmond, Victoria, Australia, 3121
- Epworth HealthCare - Richmond
-
Ringwood East, Victoria, Australia, 3135
- Genesis Care - Ringwood (formerly RROC)
-
St Albans, Victoria, Australia, 3021
- Sunshine Hospital
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6149
- Fiona Stanley Hospital
-
-
-
-
-
Salzburg, Austria, 5020
- Salzburger Landeskliniken - Universitätsklinikum Salzburg
-
-
-
-
-
Kortrijk, Belgium, 8500
- AZ Groeninge Kortrijk- Campus Kennedylaan
-
-
-
-
-
Dublin, Ireland, Dublin 18
- Beacon Private Hospital
-
Dublin, Ireland, Dublin 7
- Mater Private Hospital
-
Dublin, Ireland, Dublin 6
- St Luke's Hospital
-
-
Co Cork
-
Cork, Co Cork, Ireland
- Cork University Hospital
-
-
Co Galway
-
Galway, Co Galway, Ireland
- Galway University Hospital
-
-
Dublin 7
-
Dublin, Dublin 7, Ireland, Dublin 7
- Mater Misericordiae University Hospital
-
-
-
-
-
Auckland, New Zealand, 1142
- Auckland City Hospital
-
Christchurch, New Zealand, 4170
- Christchurch Hospital
-
Palmerston North, New Zealand, 4442
- Palmerston North Hospital
-
-
-
-
-
Ljubljana, Slovenia, 1000
- The Institute Of Oncology
-
-
-
-
-
Salamanca, Spain, 37007
- Hospital Universitario de Salamanca
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)
-
-
Gipuzkoa
-
Donostia, Gipuzkoa, Spain, 20014
- Hospital Donostia
-
-
-
-
-
Bath, United Kingdom, BA1 3NG
- Royal United Hospital Bath
-
Cambridge, United Kingdom
- Addenbrookes Hospital
-
London, United Kingdom, SE1 9RT
- Guys and St Thomas Hospital
-
London, United Kingdom, NW1 2BU
- University of London Hospital
-
London, United Kingdom, W6 8RF
- Charring Cross Hospital: Imperial College Healthcare NHS Trust
-
Nottingham, United Kingdom, NG5 1PB
- Nottingham City Hospital- City Campus
-
-
Cardiff
-
Whitchurch, Cardiff, United Kingdom, CF14 2TL
- Velindre Hospital
-
-
Hampshire
-
Southampton, Hampshire, United Kingdom, SO16 6YD
- University Hospital Southhampton
-
-
Kent
-
Canterbury, Kent, United Kingdom, CT1 3NG
- Kent and Canterbury Hospital
-
-
London
-
Chelsea, London, United Kingdom, SW3 6JJ
- Royal Marsden Hospital
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH4 2XU
- Western General Hospital
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Men with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy.
Inclusion Criteria:
Pathological diagnosis of adenocarcinoma of the prostate, judged to be at high risk for recurrence based on any of the following (in accordance with the International Society of Urological Pathology (ISUP) Consensus 2005:
Gleason score 8-10 OR Gleason score of 4+3 AND clinical T2b-4 AND PSA >20ng/mL OR N1 disease (involvement of lymph nodes at or below the bifurcation of the common iliac arteries) defined radiologically as greater than 10mm on short axis using standard CT or MRI, or biopsy proven
- Age ≥18 years
- Adequate bone marrow function Haemoglobin (Hb) ≥100g/L and White Cell Count (WCC) ≥ 4.0 x 109/L and platelets ≥100 x 109/L
- Adequate liver function: Alanine transaminase (ALT) < 2 x ULN and bilirubin < 1.5 x Upper Limit of Normal (ULN), (or if bilirubin is between 1.5 - 2 x ULN, they must have a normal conjugated bilirubin).
- Adequate renal function: calculated creatinine clearance > 30 ml/min (Cockcroft-Gault)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Study treatment both planned and able to start within 7 days of randomisation.
- Willing and able to comply with all study requirements, including treatment, and attending required assessments
- Has completed the baseline HRQOL questionnaires UNLESS is unable to complete because of literacy or limited vision
- Signed, written, informed consent
Exclusion Criteria:
- Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components
- Involvement of lymph nodes superior to the common iliac bifurcation, and/or outside the pelvis (distant lymph nodes). Lymph node involvement is defined by histopathological confirmation, or by a short axis measurement >10mm on standard imaging (CT or MRI, but not PET).
- Any contraindication to external beam radiotherapy
History of
- seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma).
- loss of consciousness or transient ischemic attack within 12 months of randomization
- significant cardiovascular disease within the last 3 months: including myocardial infarction, unstable angina, congestive heart failure (NYHA grade II or greater), ongoing arrhythmias of Grade > 2 , thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
- Evidence of metastatic disease: minimum imaging required Computed tomography scan (CT) / Magnetic Resonance Imaging (MRI) of the abdomen and pelvis, and Whole Body Bone Scan (WBBS). If equivocal bone scan, follow-up plain films are required to show NO evidence of cancer if not covered by CT/MRI
- PSA > 100 ng/mL
- History of another malignancy within 5 years prior to randomisation except for non-melanomatous carcinoma of the skin; or, adequately treated, non-muscle-invasive urothelial carcinoma of the bladder (i.e. Tis, Ta and low grade T1 tumours).
Concurrent illness, including severe infection that might jeopardize the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety
- Human Immunodeficiency Virus (HIV)-infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant enzalutamide.
- Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse;
- Patients who are sexually active and not willing/able to use medically acceptable forms of barrier contraception.
Use of hormonal therapy or androgen deprivation therapy, including enzalutamide, except in the following setting:
- Use of LHRHA (with or without anti-androgens) for less than 30 days prior to randomisation in the trial.
- Bilateral orchidectomy or radical prostatectomy
- Prior brachytherapy or other radiotherapy that would result in an overlap of radiotherapy fields
- Participation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases.
- Major surgery within 21 days prior to randomisation
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of enzalutamide, including difficulty swallowing tablets
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Enzalutamide
Enzalutamide 160 mg daily, by mouth, for 24 months from randomisation.
All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)
|
|
Active Comparator: Conventional Non-steroidal Anti-androgen (NSAA)
Conventional Non-steroidal Anti-androgen (NSAA), by mouth, for 6 months from randomisation. All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metastasis-free survival
Time Frame: 5 years
|
Metastasis free survival (MFS) is defined as the interval from the date of randomisation to the date of first evidence of metastasis or death from any cause, whichever occurs first, or the date of last known follow-up alive and without metastases. Evidence of metastasis includes findings on whole body bone scan (WBBS) or CT or MRI that are either characteristic of metastatic prostate cancer, and/or confirmed by other test results, e.g. cytology or histopathology, and lesion qualifies as new metastatic disease per RECIST 1.1. Detection of metastasis by other modalities, eg Ga-68 PSMA (Prostate Specific Membrane Antigen) PET, does not constitute an event unless confirmed by WBBS or CT or MR |
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 5 years
|
Overall survival (OS) is defined as the interval from the date of randomisation to date of death from any cause, or the date of last known follow-up alive.
|
5 years
|
Prostate cancer-specific survival
Time Frame: 5 years
|
Prostate cancer-specific survival is defined as the interval from the date of randomisation to the date of death from prostate cancer, or the date of last known follow-up alive.
|
5 years
|
PSA (Prostate-Specific Antigen) progression-free survival
Time Frame: 5 years
|
PSA progression-free survival is defined as the interval from the date of randomisation to the date of first evidence of PSA progression, clinical progression, or death from any cause, whichever occurs first, or the date of last known follow-up without PSA progression and without clinical progression. PSA progression as defined by the Phoenix criteria: an increase in PSA of more than 2ng/mL above the nadir (lowest) PSA level. |
5 years
|
Clinical progression-free survival
Time Frame: 5 years
|
Clinical progression-free survival is defined as the interval from the date of randomisation to the date of first clinical evidence of disease progression or death from any cause, whichever occurs first, or the date of last known follow-up alive without clinical progression. Clinical evidence of disease progression includes evidence of progression or recurrence on imaging, clinical examination, development of symptoms attributable to cancer progression, or initiation of other anticancer treatment for prostate cancer. |
5 years
|
Time to subsequent hormonal therapy
Time Frame: 5 years
|
Time to subsequent hormone therapy is the interval from randomisation to the first date that androgen deprivation therapy is recommenced for the treatment of recurrent (or progressive) prostate cancer, or the date of last known follow-up without recommencement of androgen deprivation therapy.
|
5 years
|
Time to castration-resistant disease (PCWG2 criteria)
Time Frame: 5 years
|
Castration resistant prostate cancer (CRPC) is defined, per PCWG2, by a rising PSA that is greater than 2ng/mL higher than the most recent nadir with a testosterone < 50 ng/dL (<1.7 nmol/L); the rise has to be at least 25% over the most recent nadir; and, the rise has to be confirmed by a second PSA at least three weeks later.
The time to castration-resistant prostate cancer is defined as the interval from randomisation to the date that the PSA first met the criteria defined above (i.e. the date of the first PSA to meet these criteria, not the date of the subsequent confirmatory test), or the date of last known follow-up without CRPC.
|
5 years
|
Safety (adverse events - CTCAE v4.03)
Time Frame: 5 years
|
The NCI Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) will be used to classify and grade the intensity of adverse events occurring until 30 days after the last dose of study treatment.
|
5 years
|
Health related quality of life (HRQL)
Time Frame: 5 years
|
HRQL will be reported by participants using the EORTC core quality of life questionnaire (QLQ C-30) and prostate cancer specific module (PR-25).
The EQ-5D-5L will be used to derive utility scores suitable for quality adjusted survival analyses
|
5 years
|
Health outcomes relative to costs (incremental cost effectiveness ratio)
Time Frame: 5 years
|
Information on the following areas of health-care resource usage will be collected: hospitalisations, visits to health professionals, and medications.
Quality-adjusted survival (QAS) time will be used to quantify the incremental effectiveness of adding enzalutamide to standard treatment.
|
5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Scott Williams, ANZUP and Peter MacCallum Cancer Centre
- Study Chair: Paul Nguyen, Dana Farber Cancer Institute and ANZUP
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANZUP1303
- ACTRN12614000126617 (Other Identifier: Australian New Zealand Clinical Trials Registry (ANZCTR))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
Clinical Trials on Enzalutamide
-
ESSA PharmaceuticalsRecruitingProstate CancerCanada, United States, Australia
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedProstate Cancer | Pharmacokinetics of EnzalutamideUnited States
-
Groupe Hospitalier Pitie-SalpetriereCompletedEpilepsy | Prostate Cancer | Neuropathy | EncephalopathyFrance
-
Radboud University Medical CenterActive, not recruitingProstatic Neoplasms, Castration-ResistantNetherlands
-
Fundación Canaria de Investigación SanitariaHospital Universitario de CanariasUnknown
-
Translational Research Center for Medical Innovation...Kagawa UniversityCompleted
-
Andreas JosefssonGöteborg University; Umeå University; Sahlgrenska University Hospital, Sweden; Sundsvall... and other collaboratorsTerminated
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
-
Macquarie University, AustraliaUnknown
-
Hinova Pharmaceuticals USA, Inc.Active, not recruitingCastration-resistant Prostate Cancer | Prostate Cancer MetastaticGermany, Spain, Denmark, France, United Kingdom, Russian Federation, Poland, Australia, Italy, Netherlands, United States, Finland, Canada, Austria